Therapeutic Drug Monitoring of Meropenem and Clinical Cure Assessment in Critically Ill Pediatric Patients: a Prospective Observational Study
Completed
- Conditions
- Critically Ill Pediatric PatientsMeropenem, Therapeutic drug monitoring, Extended infusion, Intermittent bolus, Critically ill, Pediatric
- Registration Number
- TCTR20200901002
- Lead Sponsor
- Clinical pharmacokinetics and pharmacogenomics research unit
- Brief Summary
In progress
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
1. Pediatric patients ranged in age from 1 month to 18 years who admit into pediatric wards in King Chulalongkorn Memorial Hospital
2. Patients were received meropenem
3. Body weight more than 3 kilograms
4. CVC or A-line
Exclusion Criteria
1. Patients were received valproic acid, probenecid, Patients were received valproic acid and probenecid
2. GFR is less than 60 ml/min/1.73 m2
3. Use or plan of ECMO and RRT
4. Penicillin allergy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Therapeutic drug monitoring of meropenem 4 and 8 h Meropenem level in plasma
- Secondary Outcome Measures
Name Time Method Therapeutic drug monitoring of meropenem 4 and 8 h clinical outcome